CHRS, US19249H1032

Coherus Oncology stock heads toward October 7 CVR distribution

Published on 10/05/2026 at 11:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coherus Oncology stock was last at USD 1.16 on October 2, while second-quarter revenue reached USD 14.31 million. Four analyst reports support a USD 7.75 average target.

CHRS, US19249H1032, Illustration mit AI erstellt.

Coherus Oncology (ISIN US19249H1032) stock was last at USD 1.16 on Nasdaq on October 2, 2026, at 4:00 p.m. ET, with a market capitalization of USD 179.2 million. The company is preparing to distribute contingent value rights on October 7, 2026, linked to proceeds from the sale or licensing of legacy biosimilar assets, according to GlobeNewswire on September 23, 2026.

CVR distribution sets the near term

GlobeNewswire reported that Coherus retained Oppenheimer to market the remaining Legacy BioSim Assets, including patents, royalties, cell lines and regulatory materials. Stockholders of record on September 30, 2026, are scheduled to receive the CVRs on October 7, 2026, although the eventual value depends on completed sales or licensing transactions.

The distribution is a defined checkpoint, but it is not a fixed cash payment. The company stated that proceeds will depend on what third parties ultimately pay for the assets, while broker procedures can affect how rights are credited to holders.

Q2 revenue rose to USD 14.31 million

Coherus reported USD 14.31 million in second-quarter 2026 revenue and a GAAP net loss of USD 20.63 million, according to Markets Insider. Revenue increased from USD 10.25 million in the comparable quarter, while the GAAP net loss narrowed from USD 41.34 million.

The operating picture still carries a financing constraint. The finance statements show USD 82.923 million in cash at June 30, 2026, while operating cash flow was negative USD 62.090 million in the second quarter, making asset monetization relevant to the companys funding profile.

Consensus target remains far above Nasdaq price

Markets Insider reported a Strong Buy analyst consensus and an average price target of USD 7.75 on September 21, 2026. The cited consensus also included H.C. Wainwrights Buy rating and USD 7.00 target.

Zacks said on October 2, 2026, that four analyst reports supported the USD 7.75 average, with forecasts from USD 4.00 to USD 10.00. Its average target lies 568.10 percent above the USD 1.16 last closing price cited on the page, a wide spread that reflects both the oncology pipeline opportunity and the companys funding risk.

Coherus Oncology stock stays near its yearly low

Coherus Oncology stock was last at USD 1.16 on Nasdaq on October 2, 2026, against a 52-week range of USD 1.09 to USD 2.62. The October 2 session showed an intraday range of USD 1.15 to USD 1.19 and volume of 1,183,174 shares.